2. Combination Therapy to Combat Antimicrobial Resistance and Optimize Therapy
Wednesday, October 2, 2013: 1:30 PM-3:30 PM
Room: The Moscone Center: 130-131 (Hall E)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify various options for combination therapy to treat patients with Gram-negative bacterial pneumonia and infections arising from Gram-positive pathogens, mycobacterium tuberculosis, and aspergillus
  • explain the combinations of agents for each of the above-described infections that have been associated with optimized outcomes

Target Audience: scientists, researchers, pharmacists, nurses, microbiologists, members-in-training, infectious diseases physicians, infectious diseases pediatricians, fellows, clinicians, academicians

Tracks: Investigative ID, Global ID, Adult ID

Moderators:  David Andes, MD, University of Wisconsin and Joshua Nosanchuk, MD, FIDSA, FACP, Albert Einstein College of Medicine

CME Credits: Maximum of 2 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-112-L01-P


D. Andes, None

J. Nosanchuk, None

N. Safdar, None

H. Chambers, Astra Zeneca: Scientific Advisor, Consulting fee
Pfizer: Scientific Advisor, Consulting fee
Trius: Grant Investigator, Scientific Advisor and Stock Options, Consulting fee, Grant recipient and Stock Options
Theravance: Scientific Advisor, Consulting fee

D. Kontoyiannis, Merck: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead: Speaker's Bureau, Speaker honorarium
Astellas: Investigator, Research grant
T2 biosystems: Investigator, Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.